In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
The following faculty has reported relationships with ineligible companies:
Stephen Liu, MD, faculty for this educational event, received a research grant from Alkermes, Bayer, Blueprint, Bristol-Myers Squibb, Elevation Oncology, Genentech, Gilead, Lilly, Merck, Merus, Nuvalent, Pfizer, Rain Therapeutics, RAPT, and Turning Point Therapeutics; and receives consulting fees from Amgen, AstraZeneca, Bayer, Beigene, Blueprint, Boehringer-Ingelheim, Bristol-Myers Squibb, Catalyst, Daiichi Sankyo, Eisai, Elevation Oncology, Genentech/Roche, Gilead, Guardant Health, Janssen, Jazz Pharmaceuticals, Lilly, MSD, Novartis, Regeneron, Sanofi, Takeda, and Turning Point Therapeutics.
Efrat Dotan, MD, faculty for this educational event, received a research grant from Lilly, Incyte, Relay, AstraZeneca, Medimmune, Zymeworks, NGM biopharmaceuticals and Ipsen; and receives consulting fees from Incyte, Taiho, G1 therapeutics, Pfizer; Helsinn, QED and Basilea.